← All Sponsors
SPONSOR

Alnylam Pharmaceuticals

Total Trials
5
Recruiting
5
Phases
Phase 3, Phase 1
Conditions studied: High Risk Cardiovascular DiseaseHypertensionHigh Cardiovascular RiskTransthyretin-Mediated AmyloidosisATTR AmyloidosisAcute Hepatic PorphyriaTransthyretin Amyloidosis With CardiomyopathyAdvanced Hepatocellular CarcinomaMetastatic Hepatocellular Carcinoma
NCT07181109 Phase 3
Recruiting

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

High Risk Cardiovascular Disease
United States, Australia, Canada View Trial →
NCT04561518
Recruiting

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Transthyretin-Mediated Amyloidosis
United States, Brazil, Bulgaria View Trial →
NCT04883905
Recruiting

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

Acute Hepatic Porphyria
United States, Belgium, France View Trial →
NCT07052903 Phase 3
Recruiting

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Transthyretin Amyloidosis With Cardiomyopathy
United States, Argentina, Australia View Trial →
NCT06600321 Phase 1
Recruiting

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma
United States, Italy, South Korea View Trial →